SAB Biotherapeutics Inc (SABS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$3.48-4.13%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Primary pillar under pressure — Operating losses improve or stabilize near negative $20 million by 2026-Q1: metric not reported.
SAB Biotherapeutics aims to grow by leveraging a manufacturing deal with Emergent BioSolutions. The company targets about $175 million in revenue by mid-2028. It is advancing clinical programs, including promising diabetes therapy potential. If operating losses and cash burn improve, the company could stabilize.
SAB Biotherapeutics is loss-making with worsening cash flow and negative earnings. Analysts expect revenue to decline sharply by 87% next year. The company faces ongoing litigation and management volatility. Failure to control losses or grow revenue could worsen its financial health.
The stock price is about 44% below our valuation level and 37% below the Street median. Analysts expect revenue to fall by 87% next year, reflecting very weak near-term growth. Our view differs by anticipating some recovery from this low base if manufacturing and clinical progress materialize.
Breaks if: Cash from operations worsens beyond negative $14.27 million by 2026-Q1
Control operating losses and cash flow burn while advancing clinical programs.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has volatile management, indicating uncertainty in its future performance.
The market appears to have low confidence in SABS, as indicated by a significant expectations gap. Valuation is aligned with peers, but the company is priced at a premium, suggesting that investors may be cautious about its future prospects.
Fundamentals are expected to remain weak in the near term, with a near 50% probability of missing expectations. Recent litigation and mixed management priorities add to the uncertainty surrounding the company's performance.
The long-term thesis hinges on the outcomes of ongoing clinical trials and the ability to navigate sector dynamics. Key factors include the performance of sector leaders and any changes in economic conditions that could impact the healthcare sector.
The most important moves since the prior daily snapshot.
Signal changed from 'cautious' to 'mixed'.
No, our read on the company is unchanged. The recent financial performance remains weak. The market backdrop has shifted, with the XLC and XLP sectors deteriorating. This creates a headwind for SABS, but the healthcare sector trends are still supportive.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 8 quarters. Operating income worsened from -$11.3M in 2024-Q3 to -$23.4M in 2026-Q2, and cash from operations remained negative each quarter, increasing from -$6.3M to -$9.8M. This indicates persistent operating losses and cash burn, showing limited progress in improving cash flow or profitability.
“Operating income was -$23.4M; cash from operations was -$9.8M.”
“Operating income was -$20.0M; cash from operations was -$14.3M.”
“Operating income was -$15.8M; cash from operations was -$16.8M.”
“Operating income was -$12.7M; cash from operations was -$13.0M.”
“Operating income was -$9.7M; cash from operations was -$7.2M.”
“Operating income was -$10.8M; cash from operations was -$7.8M.”
“Operating income was -$10.0M; cash from operations was -$9.5M.”
“Operating income was -$11.3M; cash from operations was -$6.3M.”
Breaks if: Operating losses worsen beyond negative $20 million by 2026-Q1
Control operating losses and cash flow burn while advancing clinical programs.
Stated as a priority in 8 quarters. Operating income worsened from -$11.3M in 2024-Q3 to -$23.4M in 2026-Q2, and cash from operations remained negative each quarter, increasing from -$6.3M to -$9.8M. This indicates persistent operating losses and cash burn, showing limited progress in improving cash flow or profitability.
“Operating income was -$23.4M; cash from operations was -$9.8M.”
“Operating income was -$20.0M; cash from operations was -$14.3M.”
“Operating income was -$15.8M; cash from operations was -$16.8M.”
“Operating income was -$12.7M; cash from operations was -$13.0M.”
“Operating income was -$9.7M; cash from operations was -$7.2M.”
“Operating income was -$10.8M; cash from operations was -$7.8M.”
“Operating income was -$10.0M; cash from operations was -$9.5M.”
“Operating income was -$11.3M; cash from operations was -$6.3M.”
Breaks if: Revenue falls below $175 million by mid-2028
Execute and maintain the Master Manufacturing Services Agreement with Emergent BioSolutions for clinical and commercial manufacturing of SAB-142.
Newly stated in 2026-Q2. Management executed a manufacturing agreement with Emergent BioSolutions for SAB-142 clinical and commercial production. This establishes a key operational partnership supporting product supply but no financial metrics are available to assess delivery.
“Entered into Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. for SAB-142.”
The next few quarters will be critical for SABS as it seeks to stabilize its fundamentals. Not investment advice.